Minireviews
Copyright ©The Author(s) 2022.
World J Hepatol. Jan 27, 2022; 14(1): 140-157
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.140
Table 5 Vaccine therapy for hepatocellular carcinoma
Vaccine
Phase
Study design
Outcome
Autologous dendritic cells (DCs) generated ex vivo in the presence of GM-CSF and IL-4[70]Phase I10 patients with unresectable primary liver cancerImmunization well tolerated without significant toxicity
Mature autologous DCs[71]Phase IITo investigate the safety and efficacy of intravenous vaccinationSafe and well tolerated with evidence of antitumor efficacy
Ilixadencel (pro-inflammatory allogeneic DCs stimulated by GM-CSF and IL-4)[72]Phase I trial17 HCC patients; As monotherapy or in combination with sorafenib to evaluate tolerabilityIncreased tumor specific CD8+ T cells in peripheral blood (73%); 1 grade 3 adverse event
GPC3 peptide[67]Open-label, phase I clinical trial33 patients with advanced HCC; To evaluate safety of GPC3 peptide, immune response, tumor response, time to tumor progression, and overall survivalGPC3 vaccination was well-tolerated; 1 patient partial response; 19 patient stable disease; 2 mo after vaccination; Measurable immune responses and antitumor efficacy
Pexa-Vec (modified poxvirus JX-594)[73]Randomized phase II dose-finding trial30 patients with advanced HCC; 3 intra-tumoral injections; To determine the optimal JX-594 doseDose related survival benefit; Increased median survival of 14.1 mo compared to 6.7 mo
Pexa-Vec (JX-594)[74]Phase 2, open-label, randomized dose finding studyPatients with advanced HCC; Intra-tumoral injection 3 times every 2 wk
Pexa-Vec (pexastimogene devacirepvec) followed by sorafenib[75]Global, randomized, open-label phase III trial (PHOCUS)459 patients will be recruited; To evaluate overall survival, time to progression, progression-free survival, overall response rate and disease control rateTrial completed; 5% adverse events